Prevents rejection in renal homotransplantation. ANDA 74069, held by Amneal. Azathioprine.
As of Nov 16, 2026, ANDA 74069 (Azathioprine), held by Amneal, was first approved by FDA on Feb 16, 1996, with 7 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Azathioprine tablets are indicated as an adjunct for the prevention of rejection in renal homotransplantation. It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. Renal Homotransplantation: Azathioprine tablets are
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 16, 1996 | Original application | Approved | None posted |
| Azathioprine50MG · tablet;oral | Azathioprine | Rx |
| Azathioprine75MG · tablet;oral | Azathioprine | Rx |
| Azathioprine100MG · tablet;oral | Azathioprine | Rx |
| Apr 23, 2019 | Supplement 14Labeling · Standard review | Approved | None posted |
| May 25, 2017 | Supplement 11Manufacturing | Approved | None posted |
| May 19, 2015 | Supplement 10Labeling · Standard review | Approved | None posted |
| Jun 21, 2011 | Supplement 6Labeling | Approved | None posted |
| Oct 23, 2008 | Supplement 4Labeling | Approved | None posted |
| Feb 1, 2007 | Supplement 3Labeling | Approved | None posted |
| Jun 22, 1999 | Supplement 1Manufacturing | Approved | None posted |
| Feb 16, 1996 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters